Meningococcal vaccine - BioPort

Drug Profile

Meningococcal vaccine - BioPort

Alternative Names: Neisseria meningitidis vaccine - BioPort

Latest Information Update: 06 Dec 2006

Price : $50

At a glance

  • Originator Emergent BioDefense Operations Lansing
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Meningococcal infections

Most Recent Events

  • 16 Jun 2003 The assets of Antex Biologics and Antex Pharma have been acquired by BioPort Corporation
  • 18 Jul 2002 This vaccine is still in active development
  • 14 May 1999 Preclinical development for Meningococcal infections in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top